Symptoms Mouches volantes (“flying flies,” “flying gnats”) are small, gray, translucent, and blurry opacities in the visual field that look like spots, threads, or dots. They are mainly subjectively visible against a bright and white background and float by with a delay when the eyes are moved. These vitreous opacities can be considered bothersome. They … Mouches Volantes
Many people suffer from the phenomenon of mouches volantes, which stands for “flying flies” in French. In this, sufferers see black dots that appear to dance in front of their eyes. Mouches volantes is harmless, but disturbs the visual sensation. The symptoms often subside on their own after a while. What is mouches volantes? Mouches … Mouches Volantes: Causes, Symptoms & Treatment
Products Pegaptanib was commercially available as a solution for injection (Macugen). It was approved in many countries in 2006 and has since been discontinued. Structure and properties Pegaptanib is an aptamer and a pegylated and modified oligonucleotide. Effects Pegaptanib (ATC S01LA03) binds to extracellular vascular endothelial growth factor (VEGF) and inhibits its activity. VEGF plays … Pegaptanib
Therapy of a complicated vitreous detachment Follow-up checks during vitreous detachment are necessary to detect possible complications at an early stage. In the course of a vitreous detachment with its many complications, the vitreous with its membrane can damage the underlying retina or even lead to a retinal detachment. This must then be treated surgically … Therapy of a complicated vitreous detachment | Vitreous humour removal
Prevention of vitreous detachment Preventing vitreous detachment is a similar attempt to prevent the body from aging in general. Of course, it is always advisable to follow a healthy lifestyle. This includes eating a balanced and varied diet, avoiding fast food products as far as possible, taking regular exercise and drinking enough every day (1.5 … Prevention of vitreous detachment | Vitreous humour removal
Course of a vitreous body lift A vitreous detachment is very variable in its duration and can last from a few days to several weeks. In some cases, the process can even last for months. The average duration is between four and twelve weeks. The symptoms can begin at the same time as the vitreous … Course of a vitreous body lift | Vitreous humour removal
Further questions about vitreous detachment The vitreous body (also known as the corpus vitreum) makes up the largest part of the human eyeball and itself consists of about 98% water. It contains hyaluronic acid chains to which the water molecules are attached, thus creating the typical gel-like consistency. In addition, the vitreous body also contains … Further questions about vitreous detachment | Vitreous humour removal
Introduction A vitreous detachment is a process in the eye in the course of which the vitreous body (also called corpus vitreum) detaches itself from the adjacent retina and is thus no longer connected to the back wall of the eye. The detachment can lead to varying degrees of visual impairment, which does not always … Vitreous humour removal
Therapy of a simple vitreous detachment A vitreous detachment without complications does not usually need to be treated.In a way, it is a natural process that takes more time for some, less time for others, but otherwise is harmless. Regular checks of the vitreous detachment and the fundus of the eye are necessary in order … Therapy of a simple vitreous detachment | Vitreous humour removal
Products VEGF inhibitors are commercially available as injectables from various suppliers. The first agent in this group to be approved was pegaptanib (Macugen) in 2004, which is now off the market in many countries. Structure and properties The currently available VEGF inhibitors are therapeutic proteins (biologics). They are antibodies, antibody fragments, and fusion proteins. They … VEGF Inhibitors
Products Ranibizumab is commercially available as a solution for injection (Lucentis). The drug was approved in the United States and many countries in 2006 and in the EU in 2007. The drug’s high price is controversial, especially when compared with bevacizumab (Avastin), which is structurally and pharmacologically similar. Bevacizumab is not approved for these indications … Ranibizumab
Products Aflibercept is marketed as an injectable (Eylea). It was approved in many countries in 2012. Structure and properties Aflibercept (C4318H6788N1164O1304S32) is a recombinant fusion protein consisting of the extracellular portions of human VEGF receptor 1 and 2 coupled to the Fc receptor of human IgG1. Effects Aflibercept (ATC S01LA05) binds the growth factors VEGF-A … Aflibercept